Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Gut Matrix
Compare Gut Matrix (PEA + BPC-157 Arginate + KPV + N-Acetyl Larazotide) prices
Lowest $/mg across vendors
Calculate dosing
Reconstitution
Enteric-coated oral capsule blend of palmitoylethanolamide (PEA), BPC-157 arginate, KPV, and N-acetyl larazotide, marketed for gut-barrier / GI support. A vendor-formulated combination; not clinically validated as a blend. Evidence is component-level only.
Component-level rationale only: PEA (a fatty-acid amide) for anti-inflammatory / PPAR-α signaling; BPC-157 for mucosal-repair signaling in rodents; KPV (an α-MSH fragment) for anti-inflammatory activity; N-acetyl larazotide (a zonulin antagonist) for tight-junction / intestinal-permeability modulation. Synergy in humans is unproven.
Vendor-created oral formulation; no human trial of the four-way combination has been published. Larazotide has the most individual clinical study (celiac-related intestinal permeability); the others are predominantly preclinical for GI use.
Typical Dose
201mg per two capsules (60 enteric-coated capsules per bottle)
Frequency
Per vendor label
Route
Oral
Notes
Enteric-coated oral capsules. Per-two-capsule content: PEA 200mg + BPC-157 arginate 250mcg + KPV 250mcg + N-acetyl larazotide 250mcg.
Aggregated from 1 lab-verified Certificate of Analysis uploaded directly by labs. Purity averages exclude values outside [50%, 100%] to filter unit-misreads.
COAs
1
Verified labs
0
Avg purity
—
Endotoxin tested
0%
This platform provides informational tools only, not medical advice. This information is for educational purposes only. Consult a licensed provider.
Disclosed Labs